[Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} has been updated with corrected structures in parts D, F, and H.

![Enzymatic deglycosylation and MS confirmation of core 1 glycosylation. MF 874.3547 untreated (A, C, E, G, I) and treated with α2-3,6,8 neuraminidase and *O*-glycosidase (B, D, F, H, J) were analyzed by LC--MS, and the spectra were evaluated by extracted ion chromatogram (EIC) for intact glycopeptide (A and B), the glycopeptide minus Neu5Ac (C and D), the Hex--HexNAc disaccharide (E and F), Neu5Ac (G and H), and the deglycosylated putative diamino acid S/TX (I and J). The \* in panel C indicates a low level of the glycopeptide minus Neu5Ac (*m*/*z* 584.2661) present in the undigested sample. Note the level of this product was considerably higher following digestion (G). In source fragmentation of SLC1G yielded the *m*/*z* 584.2661 product (\# in panel C) at the same retention time as the undigested glycopeptide.](id-2019-00068n_0001){#fig2}

[Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} has been updated with corrected structure in part E.

![Confirmation of seryl-leucine peptide and SLC1G structure. EIC for *m*/*z* 219.1328 in LC--MS spectra of α2-3,6,8 neuraminidase and *O*-glycosidase treated MF 874.3547 (A) and seryl-leucine standard (C). MS/MS of *m*/*z* 219.1328 from α2-3,6,8 neuraminidase and *O*-glycosidase treated MF 874.3547 (B) and the seryl-leucine standard (D). The confirmed structure of Neu5Acα2-3Galβ1-3GalNAcα1-O-SerLeu for MF 874.3547 (E).](id-2019-00068n_0002){#fig3}

Figures S3 in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.9b00068/suppl_file/id9b00068_si_001.pdf) has been updated with corrected structures. The corrected Supporting Information file is with this Correction.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsinfecdis.9b00068](http://pubs.acs.org/doi/abs/10.1021/acsinfecdis.9b00068).Figure S1, presence of SLC1G in TB patients and healthy controls; Figure S2, demonstration of Neu5Ac with an α2-3 linkage as the terminal sugar of SLC1G; Figure S3, activity of α2-3 neuraminidase or α2-3,6,8 neuraminidase and *O*-glycosidase on commercial oligosaccharide standards; Figure S4, LC--MS chromatograms of diamino acid standards and of α2-3,6,8 neuraminidase and *O*-glycosidase treated SLC1G; Figure S5, fold change of SLC1G levels during treatment and SLC1G abundance associations to GeneXpert and PETCT measurements based on individual patients; Table S1, transcript levels for potential SLC1G source protein in Catalysis Study patients ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsinfecdis.9b00068/suppl_file/id9b00068_si_001.pdf))
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